No headlines found.
ACCESSWIRE (Tue, 21-Jan 8:02 AM ET)
Sunshine Biopharma Announces the Appointment of New Chief Commercial Officer
ACCESSWIRE (Wed, 15-Jan 8:02 AM ET)
Sunshine Biopharma Announces Novel Inhibitor for Sars Coronavirus
ACCESSWIRE (Mon, 9-Dec 7:32 AM ET)
Sunshine Biopharma Launches a New Generic Prescription Drug
ACCESSWIRE (Wed, 4-Dec 4:06 PM ET)
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. The company is conducting a proprietary drug development program which is comprised of (i) K1.1 mRNA targeted for liver cancer, (ii) SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections, and (iii) Adva-27a for pancreatic cancer. The company has two reportable segments: Prescription Generic Pharmaceuticals ("Generic Pharmaceuticals") and Nonprescription Over-The-Counter Products ("OTC Products"). The company generates the majority of its revenue from the Generic Pharmaceuticals segment.
Sunshine Biopharma trades on the NASDAQ stock market under the symbol SBFM.
As of March 4, 2025, SBFM stock price declined to $2.13 with 48,659 million shares trading.
SBFM has a beta of 3.07, meaning it tends to be more sensitive to market movements. SBFM has a correlation of 0.04 to the broad based SPY ETF.
SBFM has a market cap of $5.77 million. This is considered a Sub-Micro Cap stock.
Last quarter Sunshine Biopharma reported $8 million in Revenue and -$.94 earnings per share. This fell short of revenue expectation by $-3 million and missed earnings estimates by -$.94.
In the last 3 years, SBFM traded as high as $19,740.00 and as low as $2.02.
SBFM has underperformed the market in the last year with a price return of -98.1% while the SPY ETF gained +14.6%. SBFM has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -23.7% and -15.1%, respectively, while the SPY returned -3.6% and -4.8%, respectively.
SBFM support price is $2.21 and resistance is $2.41 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SBFM shares will trade within this expected range on the day.